Novo Nordisk A/S (Novo Nordisk A/S) FCF Margin %

: -10.45% (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Novo Nordisk A/S's Free Cash Flow for the three months ended in Dec. 2023 was $-1,007 Mil. Novo Nordisk A/S's Revenue for the three months ended in Dec. 2023 was $9,636 Mil. Therefore, Novo Nordisk A/S's FCF Margin % for the quarter that ended in Dec. 2023 was -10.45%.

As of today, Novo Nordisk A/S's current FCF Yield % is 1.83%.

The historical rank and industry rank for Novo Nordisk A/S's FCF Margin % or its related term are showing as below:

NVO' s FCF Margin % Range Over the Past 10 Years
Min: 23.53 Med: 29.84 Max: 36.24
Current: 29.95

During the past 13 years, the highest FCF Margin % of Novo Nordisk A/S was 36.24%. The lowest was 23.53%. And the median was 29.84%.

NVO's FCF Margin % is ranked better than
94.47% of 1030 companies
in the Biotechnology industry
Industry Median: -149.715 vs NVO: 29.95

Novo Nordisk A/S FCF Margin % Historical Data

The historical data trend for Novo Nordisk A/S's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

29.14

23.53

33.82

36.24

30.14

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																1.93	46.87	39.67	51.66	-10.45

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's FCF Margin % falls into.

Novo Nordisk A/S FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Novo Nordisk A/S's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	10243.46	/	33982.121
	=	30.14 %

Novo Nordisk A/S's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1007.345	/	9636.42
	=	-10.45 %

Novo Nordisk A/S FCF Margin % Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.